〔Abstract〕 Objective To observe the clinical efficacy of high flux hemodialysis combined with hemoperfusion in the treatment of end-stage diabetic nephropathy. Methods From March 2018 to March 2019, 100 patients with end-stage diabetic nephropathy treated at Hexian Memorial Hospital of Guangzhou Panyu District were selected and divided into control group and observation group according to different dialysis regimens with 50 cases in each group. The patients in the control group were treated with low flux hemodialysis combined with hemoperfusion, and the patients in the observation group were treated with high flux hemodialysis combined with hemoperfusion. The indexes of chronic inflammatory state [interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) were compared between the two groups, high-sensitivity C-reactive protein (HS – CRP)], β2 microglobulin urea reduction rate (URR), urea clearance index (KT/V), adverse events related to dialysis and complications in two groups were compared. Results Serum IL-6 and TNF-α、hs-CRP in the group were decreased, and these indexes in the observation group was lower than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in URR and KT / V between the two groups before and after treatment (P > 0.05), β2 microglobulin were decreased, and β2 microglobulin in the observation group was lower than that in the control group, the difference was statistically significant (P < 0.05) There was no dialysis related adverse events and complications in the two groups. Conclusion High flux hemodialysis combined with hemoperfusion is effective in the treatment of end-stage diabetic nephropathy. Compared with low flux hemodialysis combined with hemoperfusion, it has considerable dialysis adequacy, and high flux hemodialysis has a better clearance effect for large and medium molecular toxins, which can effectively improve the chronic inflammatory state of patients.